Your browser doesn't support javascript.
loading
COVID-19 infections post-vaccination by HIV status in the United States
Sally B Coburn; Elizabeth Humes; Raynell Lang; Cameron Stewart; Brenna C Hogan; Kelly A Gebo; Sonia Napravnik; Jessie K Edwards; Lindsay E Browne; Lesley S Park; Amy C Justice; Kirsha Gordon; Michael A Horberg; Julia M Certa; Eric Watson; Celeena R Jefferson; Michael J Silverberg; Jacek Skarbinski; Wendy A Leyden; Carolyn F Williams; Keri N Althoff.
Affiliation
  • Sally B Coburn; Johns Hopkins Bloomberg School of Public Health
  • Elizabeth Humes; Johns Hopkins Bloomberg School of Public Health
  • Raynell Lang; Johns Hopkins Bloomberg School of Public Health, University of Calgary
  • Cameron Stewart; Johns Hopkins Bloomberg School of Public Health
  • Brenna C Hogan; Johns Hopkins Bloomberg School of Public Health
  • Kelly A Gebo; Johns Hopkins School of Medicine
  • Sonia Napravnik; University of North Carolina at Chapel HIll
  • Jessie K Edwards; University of North Carolina at Chapel Hill
  • Lindsay E Browne; University of North Carolina at Chapel Hill
  • Lesley S Park; Standford Center for Population Health Sciences
  • Amy C Justice; Yale Schools of Public Health and MEdicine, VA Connecticut Healthcare System
  • Kirsha Gordon; Yale School of Medicine, VA Connecticut Healthcare System
  • Michael A Horberg; Kaiser Permanente Mid-Atlantic Permanente Research Institute
  • Julia M Certa; Kaiser Permanente Mid-Atlantic Permanente Research Institute
  • Eric Watson; Kaiser Permanente Mid-Atlantic Permanente Research Institute
  • Celeena R Jefferson; Kaiser Permanente Mid-Atlantic Permanente Research Institute
  • Michael J Silverberg; Kaiser Permanente Northern California
  • Jacek Skarbinski; Kaiser Permanente Northern California
  • Wendy A Leyden; Kaiser Permanente Northern California
  • Carolyn F Williams; Division of AIDS at National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Keri N Althoff; Johns Hopkins Bloomberg School of Public Health
Preprint in English | medRxiv | ID: ppmedrxiv-21267182
ABSTRACT
ImportanceRecommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. ObjectiveEstimate the risk of breakthrough infections among fully vaccinated people with (PWH) and without (PWoH) HIV in the US. Design, setting, and participantsThe Corona-Infectious-Virus Epidemiology Team (CIVET)-II cohort collaboration consists of 4 longitudinal cohorts from integrated health systems and academic health centers. Each cohort identified individuals [≥]18 years old, in-care, and fully vaccinated for COVID-19 through 30 June 2021. PWH were matched to PWoH on date fully vaccinated, age group, race/ethnicity, and sex at birth. Incidence rates per 1,000 person-years and cumulative incidence of breakthrough infections with 95% confidence intervals ([,]) were estimated by HIV status. Cox proportional hazards models estimated adjusted hazard ratios (aHR) of breakthrough infections by HIV status adjusting for demographic factors, prior COVID-19 illness, vaccine type (BNT162b2, [Pfizer], mRNA-1273 [Moderna], Jansen Ad26.COV2.S [J&J]), calendar time, and cohort. Risk factors for breakthroughs among PWH, were also investigated. ExposureHIV infection OutcomeCOVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after an individual was fully vaccinated. ResultsAmong 109,599 individuals (31,840 PWH and 77,759 PWoH), the rate of breakthrough infections was higher in PWH versus PWoH 44 [41, 48] vs. 31 [29, 33] per 1,000 person-years. Cumulative incidence at 210 days after date fully vaccinated was low, albeit higher in PWH versus PWoH overall (2.8% versus 2.1%, log-rank p<0.001, risk difference=0.7% [0.4%, 1.0%]) and within each vaccine type. Breakthrough infection risk was 41% higher in PWH versus PWoH (aHR=1.41 [1.28, 1.56]). Among PWH, younger age (18-24 versus 45-54), history of COVID-19 prior to fully vaccinated date, and J&J vaccination (versus Pfizer) were associated with increased risk of breakthroughs. There was no association of breakthrough with HIV viral load suppression or CD4 count among PWH. Conclusions and RelevanceCOVID-19 vaccination is effective against infection with SARS-CoV-2 strains circulating through 30 Sept 2021. PWH have an increased risk of breakthrough infections compared to PWoH. Recommendations for additional vaccine doses should be expanded to all PWH.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2021 Document type: Preprint
...